Studies developed by physicians from the Oncology departments of Hospital Beatriz Ângelo ( HBA) and Hospital da Luz Lisboa have just been published in two renowned scientific journals: The Oncologist (the official publication of the Society for Translational Oncology) and the American Journal of Translational Research (AJTR). The article published in AJTR , last September 15, resulted from work developed in collaboration between HBA, Hospital da Luz Lisboa and IPO de Lisboa, among 108 women with breast cancer followed in these three hospitals. Entitled “Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2 + breast cancer”, the studies evaluated the variation of expression of HER2 protein in breast cancer cells , after treatment with chemotherapy and anti-HER2 antibodies before breast surgery, and its impact in prognosis. The authors verified that the loss of HER2 expression, although quite rare, has a negative impact on patient survival. If confirmed by further studies, these results open the way for clinical studies in this population of patients with breast cancer. The authors are Francisco Paralta Branco, João Moreira Pinto, João Godinho, Pedro Simões, Mafalda Casa-Nova and Rosa Madureira (all from HBA), António Moreira, Duarte Machado, Margarida Brito and Saudade André (all from IPO de Lisboa), Filipa Silva, Ana Catarino and José Luís Passos Coelho (all from Hospital da Luz Lisboa). “Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer” The article published in The Oncologist , in October edition, is a retrospective study for the evaluation of ONKOTEV as predictive score of risk of venous thromboembolism (a frequent complication in oncologic patients ) in patients with pancreatic cancer . The study included 165 patients followed at HBA between February 2012 and May 2017, showing that patients with pancreatic cancer and ONKOTEV values of 2 or higher had a 40-70% incidence of thromboembolic events, respectively, confirming the predictive value of the score. These results suggest that prophylactic anticoagulation may have a role in such patients. The article “ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer – A Retrospective Analysis” has for authors João Godinho, Mafalda Casa-Nova, João Moreira Pinto, Pedro Simões, Francisco Paralta Branco, Luísa Leal Costa, Ana Faria, Fábio Lopes, José Alberto Teixeira and José Luís Passos Coelho, oncologists from Hospital Beatriz Ângelo. “ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer - A Retrospective Analysis”
